PIK3CA相关过度生长谱的药物重定位:从过度生长综合征到肾脏病
本文综述PI3Kα通路在单基因过度生长综合征与多种肾脏病中的作用。alpelisib治疗PIK3CA相关过度生长综合征患者后肾功能改善,其肾小球上皮细胞检出PIK3CA嵌合变异,提示该通路嵌合变异或可解释部分病因未明的慢性肾脏病,PI3Kα有望成为多种肾病的新治疗靶点。
要点
- alpelisib治疗PIK3CA相关过度生长综合征患者后肾功能改善
- 肾小球上皮细胞检出PIK3CA嵌合变异,提示与病因未明CKD相关
- PI3Kα通路亦涉及狼疮肾炎、糖尿病、常染色体显性多囊肾病
核心结论
- PI3Kα通路参与单基因过度生长综合征及多种肾脏病,是潜在的新型治疗靶点。
研究设计与样本
- 综述,总结PI3Kα通路在单基因疾病与肾脏病中作用的现有证据。
主要发现
- alpelisib治疗PIK3CA相关过度生长综合征有效,一例伴非特异性肾小球病变患者治疗后肾功能改善。
- 该患者肾小球上皮细胞检出PIK3CA嵌合变异,提示PI3Kα通路嵌合变异或可解释病因未明的慢性肾脏病。
- PI3Kα通路的有害作用还涉及狼疮肾炎、糖尿病和常染色体显性多囊肾病。
- PI3Kα参与系膜细胞、小管细胞和免疫细胞等多种细胞类型。
临床怎么用
- 对PIK3CA相关过度生长综合征患者应关注肾功能,alpelisib治疗可能改善肾功能。
- 病因未明的慢性肾脏病可考虑PI3Kα通路嵌合变异的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phosphoinositide 3-kinase α (PI3Kα) is a ubiquitous lipid kinase that transduces extracellular growth, proliferation, and metabolism signals. Genes involved in the PI3Kα signaling pathway are frequently mutated in cancer. Apart from malignant conditions, monogenic rare disorders, called PIK3CA-related overgrowth syndromes, are also caused by mosaic mutations in PIK3CA, the gene encoding the catalytic subunit of PI3Kα, resulting in increased signaling promoting abnormal growth and proliferation. Recent studies have shown that alpelisib, a PI3Kα inhibitor initially designed for breast cancer, is also effective at treating PIK3CA-related overgrowth syndrome. Linking rare malformation syndromes and kidney disease, the improvement of kidney function following treatment with alpelisib in a patient with PIK3CA-related overgrowth syndrome with nonspecific glomerular lesions shed light on the involvement of PI3Kα across various nephropathies. Moreover, the identification of a PIK3CA mosaic variant in his glomerular epithelial cells suggested that mosaic variants of the PI3Kα pathway might explain cases of chronic kidney disease of undetermined etiology. Finally, the deleterious role of the PI3Kα pathway also extends to a wide variety of kidney diseases, such as lupus nephritis, diabetes, or autosomal dominant polycystic kidney disease. In unrelated disorders, PI3Kα involvement has been reported in various cell types, such as mesangial, tubular, and immune cells. This review aims at summarizing the available evidence on the involvement of the pathway in monogenic disorders and kidney disease, highlighting PI3Kα as a potential novel therapeutic target in various nephropathies.
引用
- Morin G, Isnard P, Canaud G, et al. Drug repurposing in PIK3CA-related overgrowth spectrum: breakthroughs from overgrowth syndromes to kidney disease. Kidney Int. 2025. PMID: 41173190. doi:10.1016/j.kint.2025.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。